Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Great advances in the sys… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Great advances in the systemic treatment in malignant melanoma patients

Artikel i vetenskaplig tidskrift
Författare Gustav Ullenhag
Johan Hansson
Lars Ny
Publicerad i Lakartidningen
Volym 114
ISSN 1652-7518
Publiceringsår 2017
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för onkologi
Språk sv
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Antibodies, Monoclonal, adverse effects, economics, pharmacology, therapeutic use, Antineoplastic Agents, adverse effects, economics, pharmacology, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, CTLA-4 Antigen, antagonists & inhibitors, Humans, Melanoma, drug therapy, economics, immunology, Mitogen-Activated Protein Kinase Kinases, antagonists & inhibitors, Oncolytic Virotherapy, Programmed Cell Death 1 Receptor, antagonists & inhibitors, Protein Kinase Inhibitors, adverse effects, economics, pharmacology, therapeutic use, Proto-Oncogene Proteins B-raf, antagonists & inhibitors
Ämneskategorier Cancer och onkologi

Sammanfattning

Great advances in the systemic treatment in malignant melanoma patients Up until a few years ago there was no systemic treatment with the capacity to  prolong overall survival for patients with advanced malignant melanoma. Several new treatments have been established in clinical practice in recent years and they belong to two main groups; checkpoint inhibitors and inhibitors of an intracellular pathway (MAP kinase). The latter drugs are only active in melanomas with an activating BRAF mutation, which is present in half of the patients. Side effect management is important and in particular for the checkpoint inhibitors, which activate the immune system and frequently provoke immune related reactions. The introduction of these new treatments has substantially improved prognosis and some patients might even be cured. Based on ongoing research, more therapeutic breakthroughs can be anticipated in the years to come.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?